Individualizing Immune Modulation & Chemotherapy (i2mc)

Stein Bergan<br>Group leader
Stein Bergan
Group leader

Research aims

Overall aim: To establish and document principles for individualized dosing in selected pharmacotherapies, mainly immunosuppression and chemotherapy.

This may be achieved by:

  • regular measurements of drugs in plasma or blood
  • the identification of variant genotypes or altered gene expression affecting drug response
  • the combination of pharmacokinetics, pharmacodynamics and pharmacogenomics, sources for individual variability in the response of specific drugs
  • biomarkers for the above
  • supportive models including Population PK/PD models and integrative models for biomarkers

Current projects

  • International biomarker working group under the International association of therapeutic drug monitoring and clinical toxicology
  • MarkIT pilot study on biomarkers in renal transplant recipients
  • Belatacept in kidney transplantation
  • Pharmacokinetics/Pharmacodynamics modeling
  • Pharmacogenetic panels; High througput screening
  • Pediatric and adult hemato-oncology
  • Immunosuppressants and pancreatic islets   

Contact information

Group leader 
Stein Bergan, Department of Pharmacology
Tel: +47 23071082; 93266214
E-mail: /